Trade Chinook Therapeutics, Inc. - KDNY CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.11 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023457% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001235% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 40.26 |
| Open | 40.28 |
| 1-Year Change | 107.42% |
| Day's Range | 40.24 - 40.35 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Aug 10, 2023 | 40.34 | 0.09 | 0.22% | 40.25 | 40.45 | 40.24 |
| Aug 9, 2023 | 40.26 | 0.03 | 0.07% | 40.23 | 40.27 | 40.22 |
| Aug 8, 2023 | 40.27 | 0.04 | 0.10% | 40.23 | 40.32 | 40.23 |
| Aug 7, 2023 | 40.27 | 0.06 | 0.15% | 40.21 | 40.33 | 40.20 |
| Aug 4, 2023 | 40.23 | 0.02 | 0.05% | 40.21 | 40.24 | 40.20 |
| Aug 3, 2023 | 40.24 | 0.09 | 0.22% | 40.15 | 40.25 | 40.15 |
| Aug 2, 2023 | 40.14 | -0.10 | -0.25% | 40.24 | 40.27 | 40.07 |
| Aug 1, 2023 | 40.24 | -0.01 | -0.02% | 40.25 | 40.41 | 40.21 |
| Jul 31, 2023 | 39.12 | 0.13 | 0.33% | 38.99 | 39.22 | 38.90 |
| Jul 28, 2023 | 39.02 | 0.07 | 0.18% | 38.95 | 39.05 | 38.90 |
| Jul 27, 2023 | 38.89 | -0.15 | -0.38% | 39.04 | 39.10 | 38.84 |
| Jul 26, 2023 | 39.03 | -0.01 | -0.03% | 39.04 | 39.07 | 38.86 |
| Jul 25, 2023 | 39.03 | -0.07 | -0.18% | 39.10 | 39.18 | 39.01 |
| Jul 24, 2023 | 39.19 | 0.31 | 0.80% | 38.88 | 39.31 | 38.86 |
| Jul 21, 2023 | 38.84 | -0.20 | -0.51% | 39.04 | 39.20 | 38.81 |
| Jul 20, 2023 | 39.04 | -0.12 | -0.31% | 39.16 | 39.27 | 38.95 |
| Jul 19, 2023 | 39.15 | -0.16 | -0.41% | 39.31 | 39.39 | 39.13 |
| Jul 18, 2023 | 39.29 | -0.04 | -0.10% | 39.33 | 39.48 | 39.28 |
| Jul 17, 2023 | 39.33 | 0.17 | 0.43% | 39.16 | 39.35 | 39.12 |
| Jul 14, 2023 | 39.18 | 0.08 | 0.20% | 39.10 | 39.19 | 39.02 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Chinook Therapeutics, Inc. Company profile
About Chinook Therapeutics Inc
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing precision medicines for kidney diseases. The Company's development programs consist of Atrasentan, BION-1301 and CHK-336. Atrasentan is a potent and selective endothelin A receptor antagonist that are developed for the treatment of proteinuric glomerular diseases. BION-1301 is an investigational humanized IgG4 monoclonal antibody that blocks APRIL binding to both the B-cell maturation antigen (BCMA), and transmembrane activator and CAML interactor (TACI), receptors, as a disease-modifying therapy for Immunoglobulin A Nephropathy (IgAN). CHK-336 is a liver-targeted oral small molecule lactate dehydrogenase (LDHA), inhibitor, which are developed for the treatment of primary hyperoxaluria.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Chinook Therapeutics Inc revenues increased from $827K to $51.6M. Net loss increased 26% to $102.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and Development-other increase from $24.8M to $66.1M (expense), Change in fair value of contingent consi increase from $1.5M to $27.3M (expense).
| Industry: | Bio Therapeutic Drugs |
400 Fairview Avenue North, Suite 900
SEATTLE
WASHINGTON 98109
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com